UNC global program for HIV prevention and treatment
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit
['FUNDING_OTHER'] · UNIV OF NORTH CAROLINA CHAPEL HILL · NIH-11238455
This program runs clinical studies to improve HIV prevention and care for children and adults living with or at risk for HIV across the southeastern US, southern Africa, and Southeast Asia.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF NORTH CAROLINA CHAPEL HILL (nih funded) |
| Locations | 1 site (CHAPEL HILL, UNITED STATES) |
| Trial ID | NIH-11238455 on ClinicalTrials.gov |
What this research studies
I would work with experienced UNC teams at sites in Chapel Hill, Greensboro, Malawi, and Vietnam that run trials for HIV prevention, vaccines, and treatment strategies. The program enrolls people newly diagnosed with HIV, people whose virus is suppressed on therapy, those with adherence challenges or drug-resistant virus, and people with co-infections like TB or hepatitis B. Visits can include medical exams, blood tests, follow-up visits, and sometimes new medications or prevention tools depending on the specific trial. The unit supports adult, prevention, vaccine, and pediatric/adolescent/maternal networks to bring proven clinical-trial methods to diverse communities.
Who could benefit from this research
Good fit: Ideal candidates include people living with HIV (newly diagnosed, stably suppressed, with adherence issues, or with drug-resistant virus), people at high risk for HIV, and children or pregnant people in the program regions, including those with TB or hepatitis B co-infections.
Not a fit: People who are not living with HIV and not at risk, those unable to access or travel to participating sites, or those with medical conditions that exclude trial participation are unlikely to benefit from joining.
Why it matters
Potential benefit: If successful, the work could lead to better prevention tools, improved treatment options, and more tailored care for people living with or at risk for HIV.
How similar studies have performed: Many past HIV clinical trials have produced major advances—like effective antiretroviral therapy and prevention with PrEP—though vaccine development remains challenging, and this program builds on that established trial infrastructure.
Where this research is happening
CHAPEL HILL, UNITED STATES
- UNIV OF NORTH CAROLINA CHAPEL HILL — CHAPEL HILL, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ERON, JOSEPH J — UNIV OF NORTH CAROLINA CHAPEL HILL
- Study coordinator: ERON, JOSEPH J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus